Stock CLN CELON PHARMA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Pharmaceuticals

Market Closed - Warsaw S.E.
Other stock markets
 11:55:43 2024-04-26 am EDT 		5-day change 1st Jan Change
15.24 PLN +1.87% Intraday chart for Celon Pharma S.A. +3.11% -1.42%
Apr. 24 Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2024 2025 2026
Capitalization 1 1,786 1,825 1,691 715.5 778.1 - -
Enterprise Value (EV) 1 1,720 1,781 1,558 659.4 753.6 764 778.1
P/E ratio 147 x 84.5 x -133 x -18.2 x -95.3 x 59.8 x -
Yield 0.2% 0.17% - 2.07% 0.62% 0.62% -
Capitalization / Revenue 17.5 x 13.1 x 8.49 x 3.68 x 3.13 x 2.84 x 2.55 x
EV / Revenue 16.8 x 12.8 x 7.82 x 3.39 x 3.03 x 2.79 x 2.55 x
EV / EBITDA 60.5 x 32.5 x 50.4 x 97.6 x 27 x 16.6 x 8.65 x
EV / FCF -24.6 x -63 x 599 x 22.6 x 42.7 x 33.9 x 19.1 x
FCF Yield -4.07% -1.59% 0.17% 4.43% 2.34% 2.95% 5.23%
Price to Book 4.01 x 4.2 x - 1.49 x 1.84 x 1.83 x -
Nbr of stocks (in thousands) 45,000 45,000 51,000 51,035 51,056 - -
Reference price 2 39.70 40.55 33.15 14.02 15.24 15.24 15.24
Announcement Date 3/19/20 3/31/21 5/2/22 4/26/23 - - -
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2024 2025 2026
Net sales 1 102.2 139.3 199.1 194.6 248.7 274.1 305
EBITDA 1 28.43 54.76 30.89 6.759 27.88 46.12 90
EBIT 1 6.898 23.88 -10.45 -37.34 -20.85 -2.37 21.1
Operating Margin 6.75% 17.14% -5.25% -19.19% -8.38% -0.86% 6.92%
Earnings before Tax (EBT) 1 7.809 22.07 -15.09 -36.45 -20.8 -3.243 37
Net income 1 11.93 21.49 -11.61 -39.28 -20.22 -2.972 31
Net margin 11.67% 15.43% -5.83% -20.18% -8.13% -1.08% 10.16%
EPS 2 0.2700 0.4800 -0.2500 -0.7700 -0.1600 0.2550 -
Free Cash Flow 1 -70 -28.26 2.6 29.2 17.67 22.53 40.73
FCF margin -68.46% -20.29% 1.31% 15.01% 7.1% 8.22% 13.36%
FCF Conversion (EBITDA) - - 8.42% 432.09% 63.36% 48.85% 45.26%
FCF Conversion (Net income) - - - - - - 131.4%
Dividend per Share 2 0.0800 0.0700 - 0.2900 0.0950 0.0950 -
Announcement Date 3/19/20 3/31/21 5/2/22 4/26/23 - - -
1PLN in Million2PLN
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2024 Q1
Net sales 1 51.26 - 52.92 41.94 52.83 45.04 149.6 43.89 68.95 48.84 49.1
EBITDA 1 16.53 - - 0.551 3.136 0.146 -16.55 -1.839 23.1 2.986 3.7
EBIT 1 - - -5.992 -11.1 -8.382 -11.56 -25.78 -13.61 11.42 -9.768 -7.65
Operating Margin - - -11.32% -26.46% -15.87% -25.67% -17.24% -31.01% 16.56% -20% -15.58%
Earnings before Tax (EBT) - - -7.113 - -8.529 -11.4 -25.04 - - - -
Net income 1 - -7.831 -4.079 -7.512 -8.11 -11.67 -27.61 -9.475 9.143 -6.815 -6.9
Net margin - - -7.71% -17.91% -15.35% -25.91% -18.46% -21.59% 13.26% -13.95% -14.05%
EPS - -0.1700 -0.1000 - -0.0100 -0.0100 - - - - -
Dividend per Share - - - - - - - - - - -
Announcement Date 9/27/19 11/29/21 5/2/22 5/25/22 9/28/22 11/23/22 4/26/23 5/24/23 9/20/23 11/22/23 -
1PLN in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 66.7 44 133 56.1 24.6 14.1 -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -70 -28.3 2.6 29.2 17.7 22.5 40.7
ROE (net income / shareholders' equity) 2.67% 4.89% -2.58% -7.6% -1.85% 2.75% -
ROA (Net income/ Total Assets) 2.07% - - - - - -
Assets 1 577.5 - - - - - -
Book Value Per Share 2 9.890 9.660 - 9.400 8.280 8.330 -
Cash Flow per Share - - - - - - -
Capex 1 65 99.2 41.4 31.5 33.7 37.7 45.1
Capex / Sales 63.52% 71.2% 20.77% 16.17% 13.55% 13.75% 14.77%
Announcement Date 3/19/20 3/31/21 5/2/22 4/26/23 - - -
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Celon Pharma S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
15.24 PLN
Average target price
16.5 PLN
Spread / Average Target
+8.27%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CELON PHARMA S.A. Stock Celon Pharma S.A.
-1.42% 192M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CLN Stock
  4. Financials Celon Pharma S.A.